Israeli Drug discovery company Compugen is developing a Predictive Structural Biology (PSB) infrastructure platform to identify the functional interaction sites of proteins, which are useful in the rational design of novel drugs.
Intended to improve discovery of functional therapeutic monoclonal antibodies in cancer and immunology, the development of the platform is based on integrating capabilities that were previously developed for Compugen's PPI Blockers Discovery Platform.
Compugen president and CEO Dr Anat Cohen-Dayag said the new capability is being designed to also allow generation of monoclonal antibodies against additional targets, such as those that have to date proven refractory to antibody targeting attempts.
"The uniqueness of the current application is its focus on functional protein regions, thereby increasing the likelihood of generating functional antibodies with the desired therapeutic activity," Dr Cohen-Dayag added.
"Furthermore, future modifications of the current application may enable us to introduce selected specificities to a given antibody in a predictable manner."
